本帖最后由 老马 于 2012-1-13 21:20 编辑
5 q- F" D( Q$ t. t! C1 O1 U P3 @- ~, P2 A ~
爱必妥和阿瓦斯丁的比较
2 x6 I9 ?' H! V9 N3 l) |
) H3 Y+ a) i! ~; C, ]( Chttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/; ?5 e7 S; e( y8 n4 [2 y& `+ ~
{$ J# G* {) i1 A4 G' N% ^1 o
0 z: @6 K( O" g% {1 Z
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/# k! Q# S9 E* V6 }5 T" Z( b
==================================================
" o. {/ Q$ M6 h8 ~, p: YOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
/ [6 \* ?& E$ M. g6 mPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
- R. W4 e2 o& ]' T9 S7 [, pResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
, f0 U( c8 f( M# C$ r4 W! R
|